Genprex Unveils Promising Preclinical Findings on TROP2 as a Biomarker in Lung Cancer Therapy

Genprex Presents Novel Insights on TROP2 as a Predictive Biomarker for Lung Cancer Treatment



In a significant development for lung cancer therapy, Genprex, Inc. has announced compelling preclinical findings suggesting that low levels of TROP2 expression might serve as a predictive biomarker for resistance to Reqorsa® (quaratusugene ozeplasmid), a revolutionary gene therapy aimed at treating non-small cell lung cancer (NSCLC). This intriguing data was shared during the prestigious 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held in Barcelona, Spain, from November 18 to 20, 2026.

Understanding TROP2 and Its Significance in Cancer Therapy


TROP2, or trophoblast cell surface antigen 2, is a protein that has recently gained attention in the oncology field. Genprex's research indicates that low expression levels of this protein might signal primary resistance to its lead candidate, Reqorsa®, highlighting the need for better patient selection in precision oncology.

Ryan Confer, the President and CEO of Genprex, emphasizes the importance of this discovery, stating, "Identifying patients likely to benefit the most from Reqorsa is crucial in advancing precision oncology." This research provides clinical insights that could pave the way for further investigations into TROP2's role—a critical step towards optimizing patient outcomes in lung cancer treatments.

Key Findings from the Research


The research showcases several notable findings:
  • - Low TROP2 Expression and Resistance: Analysis of lung cancer cell lines and patient-derived organoids revealed that nearly half of the evaluated models exhibited primary resistance to TUSC2 gene delivery linked to low TROP2 expression, indicating its potential as a resistant marker.
  • - Clinical Validation: In support of their hypothesis, an analysis of pretreatment tumor biopsies demonstrated an association between TROP2 expression levels and patient treatment responses in ongoing clinical trials, solidifying TROP2’s role as a predictive biomarker.
  • - Modulation of TROP2 Increases Treatment Sensitivity: The ability to alter TROP2 levels showed promising results in enhancing treatment efficacy. Adding TROP2 to low-expressing NSCLC cells significantly heightened sensitivity to TUSC2-induced apoptosis. Conversely, decreasing TROP2 expression in higher expressing cells resulted in increased sensitivity, indicating a dual opportunity for therapeutic applications.

Implications of the Findings


These preclinical findings could revolutionize the approach to lung cancer treatment, where personalized therapies based on specific biomarker profiles are becoming the norm. The potential to enhance Reqorsa's efficacy through TROP2 modulation opens new avenues for combination strategies in treating resistant NSCLC cases, a area that has long posed challenges in oncology.

However, despite these promising initial findings, Genprex acknowledges the need for further research - both preclinical and clinical - to conclusively establish TROP2's predictive utility and its role in enhancing treatment outcomes. As lung cancer remains one of the leading causes of cancer-related deaths globally, advancing such biomarker-driven approaches is essential for improving the precision of treatment plans.

Future Prospects


Moving forward, Genprex plans to deepen its investigation into TROP2’s function and its therapeutic applications in upcoming studies. The company continues to develop Reqorsa® using its innovative Oncoprex® Delivery System, making strides towards the FDA-approved clinical trials for both non-small cell and small cell lung cancer. Additionally, the FDA has granted Fast Track Designation to both lung cancer programs, further highlighting the potential impact of Genprex’s therapies.

In summary, Genprex’s new findings on TROP2 not only enhance our understanding of biomarker-driven therapy in lung cancer but also hold promise for more personalized treatment approaches that could effectively target this challenging disease. By harnessing innovative gene therapies like Reqorsa®, there is potential to significantly improve patient outcomes and carve a path towards more successful cancer therapeutics.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.